Compounds 1, 5, and doxorubicin displayed cytotoxic effects towards the 9 tested cancer cell lines with IC50 values varying from 14.44 μM (against CCRF-CEM leukemia cells) to 44.20 μM (against the resistant HCT116 (p53−/−) cells) for 1 and from 38.46 μM (against CEM/ADR5000 cells) to 112.27 μM (against the resistant HCT116 (p53−/−) cells) for 5. The gene discussed is TP53; the disease is cancer.